Developing an algorithm for Molecular Tailored Therapy

The team previously conducted a pilot trial that demonstrated the feasibility of delivering Molecularly Tailored Therapy (MTT) for metastatic pancreatic cancer patients. In this project, they are evaluating the benefits of MTT versus physician-selected standard of care for patients with metastatic disease. In addition, they are leveraging the findings from the clinical trial to interrogate and define a set of network models representing major relevant changes in pancreatic cancer cells that associate significantly with response or resistance to standard therapies. This work is expected to culminate in a version 2.0 molecular algorithm for the next, larger clinical trial. The team is also defining novel chemoresistance mechanisms and identifying targets to overcome such resistance in pancreatic cancer cells.